Videoconference

Adapt and overcome to the Covid-19 crisis April 23, 2020



Product portfolio progression

Clinical stage

With Teva Pharmaceuticals

- *mdc-IRM* (*maintenance treatment of schizophrenia*)
- mdc-TJK (antipsychotic)

With AIC

• *mdc*-CWM (post-operative pain and inflammation)

Product portfolio progression

Next potential candidates for clinical development

With the Bill & Melinda Gates Foundation

• *mdc*-WWM (contraception)

Internal products internes

- *mdc*-GRT (Organ transplant)
- mdc-NVA (Pain)
- *mdc*-KPT (Animal Health / Pain)

Product portfolio progression

Other recent developments

• mdc-CMV (surgical anaesthesia and 3 days of postoperative analgesia)

With Unitaid

• \$ 6,4 millions grant for a a 3-month acting injectable ivermectin to neutralize the transmission vector of Malaria

With the Bill & Melinda Gates Foundation

 Start of activities for a product aiming at preventing HIV infection, preexposure prophylaxis (PrEP)

The third path to fight Covid-19

Prevention

Actions taken in response to the Covid-19 crisis



You can send your questions by using the chat on the right of your screen

MedinCell

Thank you

MedinCell 3, rue des frères Lumière 34830 Jacou • France

www.medincell.com